Tag: IXC

Invex Therapeutics ASX IXC Idiopathic Intracranial Hypertension headache

Invex Therapeutics raises $26 million as it plans for Phase 3 clinical trial

Two days since publishing its Phase 2 clinical trial results and announcing “clear evidence” that its Exeatide drug is effective at reducing intracranial pressure in Idiopathic Intracranial Hypertensi...
Read more
Invex Therapeutics ASX IXC repurpose diabetic drug brain disorders Exenatide IPO

Invex Therapeutics aims to repurpose a diabetic drug for brain disorders

Biopharmaceutical company Invex Therapeutics is planning to make its ASX debut this week under the ticker code “IXC” with ambitions to repurpose an approved diabetes drug for some neurological conditi...
Read more

RECENT POSTS

STOCK SUMMARY

INVESTOR TOOLS

FOLLOW US

HOT TOPICS

TRENDING POSTS

Small Caps ASX Australian stock market
Small Caps is Australia's #1 site for news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
Copyright 2020 Small Caps. All rights reserved.